Sarah Sammons, MD, medical oncologist, clinical investigator in the Breast Oncology Center, associate director of the ...

Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2 ...

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--The HERTHENA-Lung02 phase 3 trial evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell ...

(RTTNews) - Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in patients with EGFR-mutated non-small cell lung cancer ...

The trial compared the ADC patritumab deruxtecan to chemotherapy in people with metastatic or locally advanced EGFR-mutated non-small cell lung cancer (NSCLC) after the failure of a third ...

The results suggest that AZ and Daiichi Sankyo could be in line for a second big win for a cancer ADC to follow Enhertu (trastuzumab deruxtecan), their HER2-directed drug which has just claimed a ...

Seagen won a lawsuit in April 2022 which claimed that Enhertu (trastuzumab deruxtecan) infringes a patient it holds (No. 10,808,039) covering antibody-drug conjugates that include auristatin ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Trastuzumab has become part of the standard of care for the treatment of patients with HER2-positive breast cancer in the metastatic as well as the adjuvant setting. Cardiotoxicity, however ...